Granata Bio has announced a major strategic development with Gedeon Richter, a global leader in women’s health. The pharmaceutical company has taken a significant equity stake in Granata Bio and will also gain representation on the company’s board of directors.
Though the financial details of the investment have not been disclosed, the deal forms the basis of a broader strategic alliance between the two companies, with a shared focus on enhancing access to fertility care. A key element of the agreement includes a binding term sheet for the U.S. co-development of BEMFOLA, Gedeon Richter’s recombinant follicle-stimulating hormone (FSH), a widely used component in ovarian stimulation treatments.
“We’re proud to partner with Gedeon Richter, an organization whose global footprint and manufacturing excellence perfectly complement Granata Bio’s strengths in the U.S. market. This collaboration brings together the best of both companies: deep therapeutic expertise, operational agility, and a shared commitment to improving access to fertility care,” said Evan Sussman, CEO and Co-Founder of Granata Bio.
Further strengthening their alignment in the fertility space, the companies have signed a royalty purchase agreement tied to Granata’s proprietary human menopausal gonadotropin (hMG) program. This agreement is expected to support long-term commercial interests for both parties.
“FSH is the most prescribed gonadotropin by volume and represents a cornerstone of ovarian stimulation treatment. The addition of BEMFOLA to our pipeline significantly strengthens our portfolio, providing coverage across all major IVF product categories. Together, these assets position us to better support the evolving needs of patients and providers in the U.S. fertility landscape,” said Stephen Medeiros, Chief Operating Officer of Granata Bio.
The partnership positions Granata Bio to leverage its presence and network within the U.S. fertility market, while drawing on Gedeon Richter’s global reach and reproductive health expertise. Granata Bio, founded in 2018, has recently expanded its capabilities with the acquisition of Oviva Therapeutics and continues to build a diverse pipeline aimed at addressing key gaps in reproductive medicine.
